COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
NCT ID: NCT04329559
Last Updated: 2021-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
21 participants
OBSERVATIONAL
2020-03-30
2021-02-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)
NCT04883177
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
NCT00629421
Non-invasive Methods for Predicting Decompensation of Chronic Liver Disease
NCT06741904
Non-invasive Diagnosis of Portal Hypertension in Cirrhosis Based on Metabolomics Technology
NCT05551884
Systemic Inflammation in Liver Cirrhosis
NCT04850534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\) Laboratory-confirmed COVID-19 infection;
* 3\) Pre-existing liver cirrhosis based on liver biopsy or clinical findings.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Renmin Hospital of Wuhan University
OTHER
LanZhou University
OTHER
Minda Hospital Affiliated to Hubei University for Nationalities
UNKNOWN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
OTHER
Tianjin Second People's Hospital
OTHER
The Sixth People's Hospital of Shenyang
OTHER
Guangxi Zhuang Autonomous Region
UNKNOWN
Shenzhen Third People's Hospital
OTHER
Ankang Central Hospital
OTHER
Xingtai People's Hospital
OTHER
Dalian Sixth People's Hospital
UNKNOWN
The Central Hospital of Lishui City
OTHER
The Affiliated Third Hospital of Jiangsu University
UNKNOWN
Suizhou Hospital, Hubei University of Medicine
UNKNOWN
Hepatopancreatobiliary Surgery Institute of Gansu Province
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaolong Qi
Chief, Institute of Portal Hypertension
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mingkai Chen, MD
Role: STUDY_CHAIR
Renmin Hospital of Wuhan University
Xiaolong Qi, MD
Role: STUDY_CHAIR
LanZhou University
Fengmei Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Tianjin Second People's Hospital
Ye Gu, MD
Role: PRINCIPAL_INVESTIGATOR
The Sixth People's Hospital of Shenyang
Zicheng Jiang, MD
Role: PRINCIPAL_INVESTIGATOR
Ankang Central Hospital
Guo Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Guangxi Zhuang Autonomous Region
Yong Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Dalian Sixth People's Hospital
Dengxiang Liu, MD
Role: PRINCIPAL_INVESTIGATOR
Xingtai People's Hospital
Qing He, MD
Role: PRINCIPAL_INVESTIGATOR
Shenzhen Third People's Hospital
Hua Yang, MD
Role: PRINCIPAL_INVESTIGATOR
Minda Hospital Affiliated to Hubei University for Nationalities
Zhengyan Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Suizhou Hospital, Hubei University of Medicine
Bin Xiong, MD
Role: PRINCIPAL_INVESTIGATOR
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Xiaodan Li, MD
Role: PRINCIPAL_INVESTIGATOR
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Hongguang Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
The Affiliated Third Hospital of Jiangsu University
Chuxiao Shao, MD
Role: PRINCIPAL_INVESTIGATOR
The Central Hospital of Lishui City
Hongmei Yue, MD
Role: PRINCIPAL_INVESTIGATOR
LanZhou University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dalian Sixth People's Hospital
Dalian, , China
Minda Hospital Affiliated to Hubei University for Nationalities
Enshi, , China
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Enshi, , China
The First Hospital of Lanzhou University
Lanzhou, , China
The Central Hospital of Lishui City
Lishui, , China
Guangxi Zhuang Autonomous Region
Nanning, , China
The Sixth Peoples Hospital of Shenyang
Shenyang, , China
Shenzhen Third People's Hospital
Shenzhen, , China
Suizhou Hospital, Hubei University of Medicine
Suizhou, , China
Tianjin Second People's Hospital
Tianjin, , China
Ankang Central Hospital
Wuhan, , China
Renmin Hospital of Wuhan University
Wuhan, , China
Wuhan Union Hospital
Wuhan, , China
Xingtai People's Hospital
Xingtai, , China
The Affiliated Third Hospital of Jiangsu University
Zhenjiang, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1. Epub 2020 Mar 4. No abstract available.
Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020 Jun;5(6):529-530. doi: 10.1016/S2468-1253(20)30084-4. Epub 2020 Mar 20. No abstract available.
Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435. Epub 2020 Mar 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHESS2002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.